This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

The Grünenthal Group Enters Into Exclusive Agreement With Horizon Pharma For Commercialization Of DUEXIS® In Latin America

Stocks in this article: HZNP

AACHEN, Germany and PANAMA CITY, June 19, 2012 /PRNewswire/ --

The Grünenthal Group today announced that it has entered into an exclusive agreement with Horizon Pharma, Inc. (NASDAQ:  HZNP), a biopharmaceutical company, for the commercialization of DUEXIS ® in Latin America.

"We are excited about strengthening our existing product portfolio in Latin America with DUEXIS ®," said Jose Maria Mora, acting Executive Vice President, Grünenthal Latin America. "The agreement with Horizon Pharma is the first strategic step for the complete coverage of the Latin American market with our pain portfolio and shows that we are an attractive partner to other pharmaceutical companies. This is very important for the long-term success of the Grünenthal business in Latin America."

"As this is our first out-license of DUEXIS ® outside the U.S., we are especially pleased to partner in Latin America with Grünenthal, a worldwide leader in the promotion of pain products," said Timothy P. Walbert, Chairman, President and Chief Executive Officer, Horizon Pharma.  

The Grünenthal Group has a long tradition and strong position in many Latin American markets. Expanding the presence in Brazil and Mexico by targeted acquisitions of companies and/or product portfolios is a key priority for this strategic development. Calculated in Euros, Grünenthal increased revenues by 14 percent in Latin America in 2011. Based on local currencies, the revenue growth was even greater. Latin America contributed 16 percent of the revenues in 2011, but it is the company's strategic objective to raise the share considerably to up to approx. 40 percent of the commercial revenues in the coming years.

About Grünenthal

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,778.15 +421.28 2.43%
S&P 500 2,061.23 +48.34 2.40%
NASDAQ 4,748.3960 +104.0840 2.24%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs